In advanced disease, the treatment with tyrosine kinase inhibitors (TKIs) is the main approach to target the majority of NSCLC driver genetic alterations including: the anaplastic lymphoma kinase gene (ALK), the proto-oncogene tyrosine-protein kinase 1 (ROS1) and the epidermal growth factor receptor (EGFR) [1, 9–12]. This evidence concerns the gene ALK and non-small cell lung carcinoma.